vaccin
repres
one
effect
copernican
revolut
humankind
world
health
innov
discoveri
edward
jenner
late
year
xviii
centuri
allow
control
complet
erad
infecti
diseas
smallpox
rinderpest
viru
immun
strategi
pose
base
current
remark
therapeut
approach
infect
also
cancer
evolutionari
term
pathogen
acquir
capabl
circumv
immun
system
sever
evas
mechan
revis
elsewher
prevent
pathogen
clearanc
establish
immun
memori
vaccin
repres
uniqu
tool
imped
pathogen
spread
therefor
urgent
need
effici
vaccin
relev
mycobacterium
tuberculosi
caus
tuberculosi
current
one
fear
infecti
agent
due
capabl
evad
immun
system
lead
death
one
million
peopl
per
year
unbeliev
licens
vaccin
mycobacterium
tuberculosi
bacillu
bcg
conceiv
year
ago
nonetheless
bcg
display
degre
inefficaci
human
thu
rais
need
new
tailor
vaccin
strategi
current
investig
moreov
everi
year
new
case
human
immunodefici
viru
hiv
infect
lead
necess
vaccin
control
prevent
spread
viru
vaccin
hiv
pass
phase
ii
clinic
trial
due
poor
protect
confer
requir
revis
deliv
antigen
ag
strategi
improv
cell
respons
moreov
recent
outbreak
ebola
viru
zika
viru
infect
clearli
demonstr
still
nowaday
infecti
diseas
need
overwhelm
report
world
health
organ
hand
vaccin
repres
also
therapeut
tool
cancer
one
hallmark
cancer
capabl
tumor
cell
evad
immunemedi
destruct
promot
toler
milieu
therefor
immun
system
push
respond
specif
robustli
tumor
cell
address
purpos
becom
evid
dendrit
cell
dc
stand
potent
tool
hand
mediat
cellular
humor
respons
dc
discov
r
steinman
z
cohn
divid
phagocyt
cell
discov
e
metchnikoff
macrophag
dc
basi
differ
effector
function
microbi
scaveng
activ
macrophag
antigenpres
function
dc
sinc
dc
emerg
potent
antigenpres
cell
capabl
shape
adapt
respons
infect
cancer
moreov
broad
spectrum
dc
activ
make
suitabl
fine
shift
type
respons
context
need
take
advantag
new
adjuv
innov
agsdeliveri
carrier
target
strategi
feasibl
optim
activ
ag
present
process
specif
dc
subset
effect
initi
adapt
respons
need
given
context
discuss
divers
phenotyp
function
properti
dc
subtyp
exploit
recent
develop
vaccin
approach
deal
advanc
use
ag
adjuv
carrier
dcsexpress
molecul
object
target
dendrit
cell
primari
profession
antigenpres
cell
apc
resid
lymphoid
nonlymphoid
organ
dc
encompass
sever
heterogen
subset
whose
subdivis
reli
ontogeni
express
surfacereceptor
transcript
factor
much
effort
done
identif
character
tissuespecif
dc
subset
unravel
correl
phenotyp
local
function
properti
health
diseas
initi
dc
classifi
convent
dc
cdc
plasmacytoid
dc
pdc
briefli
cdc
prime
cell
orchestr
agspecif
adapt
respons
pdc
interven
viral
infect
produc
type
interferon
ifn
advanc
approach
extrem
push
understand
dc
biolog
result
recent
readapt
taxonomi
inde
villani
colleagu
identifi
six
subset
dc
monocyt
human
figur
dc
dc
dc
dc
pdc
repres
crosspres
dc
correspond
cdc
display
antigen
uptak
process
capabl
seem
prone
respond
virus
phenotyp
close
monocyt
repres
newli
defin
subset
share
featur
pdc
cdc
even
though
appear
function
differ
pdc
similar
cdc
inde
local
cell
zone
tonsil
probabl
promot
fast
adapt
immun
due
fine
cluster
correspond
pure
pdc
popul
precis
classif
open
way
accur
view
dc
role
patholog
provid
cue
specif
target
immunotherapi
inde
reason
assum
extrem
phenotyp
divers
correl
differ
intrins
function
properti
dc
emerg
villani
work
addit
environment
cue
dictat
dc
activ
drive
specif
cell
respons
inde
dc
display
plethora
pattern
recognit
receptor
prr
specif
bound
microb
damageassoci
molecular
pattern
pamp
damp
respect
upon
receptor
engag
peripher
tissu
transduct
signal
lead
dc
matur
upregul
costimulatori
molecul
refer
signal
pivot
chemokin
receptor
allow
dc
migrat
affer
lymphat
vessel
drain
lymph
node
ln
parallel
dc
mediat
ag
proteolysi
present
intracellular
peptid
major
histocompat
complex
mhc
class
cell
exogen
peptid
mhc
ii
cell
refer
signal
dc
present
exogen
ag
mhc
class
socal
crosspresent
allow
induc
cytotox
lymphocyt
ctl
virus
tumor
cell
inde
ln
matur
dc
encount
cognat
cell
initi
adapt
respons
absenc
matur
steadyst
condit
ag
present
consequ
migrat
ln
promot
peripher
toler
via
cell
anergi
regulatori
cell
format
depend
receptor
engag
dc
display
differ
matur
state
produc
differ
inflammatori
mediat
often
refer
signal
impact
follow
cellular
humor
respons
three
signal
releas
dc
drive
helper
th
cell
differenti
briefli
dc
educ
cell
intracellular
bacteria
promot
polar
th
type
cell
upon
infect
multicellular
parasit
dc
help
basophil
polar
cell
th
type
cell
produc
mainli
special
mucos
skin
immun
dc
drive
activ
th
type
thu
polar
cell
crucial
event
provid
mechan
specif
orchestr
restor
physiolog
homeostasi
dc
undergo
apoptosi
fulfil
function
rapid
dc
turnov
activ
necessari
avoid
excess
cell
activ
maintain
selftoler
lymphocyt
activ
culmin
establish
immunolog
memori
provid
host
cell
prone
effici
respond
reinfect
pathogen
upon
tumor
relaps
besid
dc
key
player
humor
respons
inde
directli
interact
b
cell
indirectli
support
activ
cell
lead
humor
memori
notion
strengthen
idea
dc
repres
optim
target
immunotherapi
vaccin
act
interfac
innat
adapt
immun
har
robust
respons
dctarget
vaccin
dc
matur
essenti
adjuv
becom
compulsori
complement
inactiv
subunit
vaccin
may
promot
suboptim
respons
furthermor
improv
dc
migrat
ag
avail
specif
target
although
seem
clear
immun
could
benefit
adjuv
use
sole
adjuv
licens
clinic
recent
alum
despit
alum
use
vaccin
practic
sinc
begin
last
centuri
mechan
activ
innat
immun
subsequ
activ
adapt
immun
respons
remain
elus
adjuv
properti
alum
initi
attribut
activ
inflammasom
nevertheless
studi
clearli
shown
dispens
gener
respons
presenc
adjuv
tlr
signal
also
dispens
alum
adjuvant
well
mast
cell
eosinophil
macrophag
recent
propos
upon
contact
alum
dc
produc
activ
src
syk
kinas
mobil
nfat
nuclear
transloc
turn
requir
optim
cell
prime
activ
antibodi
product
addit
alum
chemic
adjuv
test
preclin
model
show
clear
heterogen
respons
driven
differ
adjuv
independ
ag
underli
need
deepen
knowledg
power
tool
drive
immun
respons
inde
oilinwat
emuls
adjuv
allow
longlast
ag
retent
drain
ln
enhanc
ag
uptak
lnresid
dc
promot
robust
humor
respons
via
follicular
dc
activ
cell
immun
induct
convers
adjuv
consist
antibacteri
peptid
synthet
oligodeoxynucleotid
odn
elicit
releas
human
dc
via
engag
endosom
tlr
support
immun
intracellular
pathogen
cancer
last
decad
attent
focus
tlr
ligand
adjuv
current
sever
compound
investig
analog
ligand
poli
c
similar
compound
act
agonist
flagellin
act
imiquimod
ligand
agonist
cpg
odn
bind
due
possibl
reactogen
may
induc
administ
tlr
agonist
compound
chemic
modifi
reduc
toxic
deliv
specif
dc
subset
interest
avoid
tlr
ligand
dissemin
monophosphoryl
lipid
lowtox
molecul
deriv
lipopolysaccharid
lp
display
promis
effect
vaccin
design
even
though
promot
termin
differenti
cell
lead
reduc
memori
protect
anoth
lpsanalog
lipid
emerg
potent
induc
agspecif
respons
codeliv
poorli
immunogen
tumor
ag
improv
effect
strength
immun
addit
effici
apc
activ
ag
process
present
aspect
taken
account
import
dcderiv
activ
adapt
respons
shown
alumdriven
immun
respons
mous
model
infect
also
test
human
cell
prime
presenc
activatori
dc
first
hour
interact
cell
activatori
monocytederiv
dc
modc
stimul
cytokin
cocktail
produc
dcderiv
turn
transpres
cell
immunolog
synaps
via
sinc
cell
start
express
mani
hour
ag
encount
dcmediat
present
complex
indispens
effici
cell
prime
propos
reason
approv
therapi
base
use
antibodi
avoid
acut
phase
autoimmun
diseas
acut
reject
kidney
heart
hand
transplant
effici
interf
cell
prime
cell
reactiv
sinc
produc
nfatdepend
manner
improv
adjuvant
prr
agonist
vaccin
purpos
capac
select
prr
agonist
induc
nfat
signal
pathway
activ
product
consid
mani
prr
ligand
shown
activ
nfat
transcript
factor
famili
member
innat
immun
cell
nfat
pathway
activ
neutrophil
macrophag
dc
respons
curdlan
also
activ
dc
respons
lp
downstream
activ
respons
mannosecap
lipoarabinomannan
manlam
major
lipoglican
mycobacterium
tuberculosi
downstream
respons
bear
fungi
product
innat
immun
cell
inflammatori
respons
relev
effici
cell
prime
also
skew
cell
activ
toward
type
respons
mice
dcderiv
one
cytokin
requir
elicit
product
nk
cell
lpsmediat
inflammatori
condit
fungal
infect
potent
activ
macrophag
favor
commit
cell
therefor
earli
releas
nk
cell
crucial
control
varieti
primari
bacteri
fungal
infect
also
induct
type
immun
memori
fundament
protect
bacteri
fungal
viral
infect
antitumor
immun
therapi
anoth
import
reason
consid
capac
activ
nfat
pathway
adjuv
select
test
repres
fact
nfat
regul
also
product
prostanoid
activ
dc
promot
activ
dc
migrat
sustain
vasodil
local
edema
format
inflammatori
process
particularli
relev
vaccin
purpos
sinc
increas
interstiti
pressur
gener
edema
forc
fluid
affer
lymphat
favor
first
wave
antigen
arriv
drain
ln
intriguingli
ln
drainag
protein
antigen
occur
rapidli
subcutan
intraderm
intramuscular
immun
thu
permit
extrem
fast
uptak
phagocyt
strateg
local
close
proxim
subcapsular
sinu
lymphat
sinu
drain
ln
antigenpres
cell
ln
maintain
homeostasi
ln
activ
adapt
immun
respons
last
decad
longheld
paradigm
migratori
dc
resid
peripher
tissu
skin
uniqu
apc
involv
cell
immun
dramat
chang
inde
subcapsular
sinu
macrophag
medullari
macrophag
lnresid
dc
ln
sentinel
avoid
excess
pathogen
dissemin
mediat
immun
respons
concern
migratori
dc
consid
skin
repres
site
utmost
import
vaccin
strategi
due
eas
access
extrem
high
presenc
dc
skinresid
dc
subdivid
epidermalresid
langerhan
cell
lc
langerin
two
divers
subset
dermal
dc
langerin
upon
infect
ddc
migrat
ln
within
h
lc
within
h
support
longlast
agpresent
sever
work
reveal
intrins
differ
two
subset
induc
th
ctl
respons
due
particular
crosspres
capabl
ddc
instanc
ln
whose
strateg
architectur
enhanc
probabl
encount
migratori
dc
cognat
cell
adapt
immun
initi
note
lnresid
dc
suffici
promot
earli
adapt
respons
independ
migratori
dc
pathogen
antigen
directli
access
lymphat
conduit
antivir
respons
lnresid
dc
play
crucial
role
thank
intrins
capabl
crosspresent
ctl
may
support
pdc
herp
simplex
viru
hsv
skin
infect
lnresid
dc
uptak
cargoantigen
ferri
skinresid
migratori
dc
order
elicit
ctl
inde
lc
ddc
synerg
lnresid
dc
stand
potent
ctl
induc
preferenti
sustain
th
respons
influenza
hsv
cutan
infect
addit
lnresid
dc
ddc
display
intrins
capabl
crosspresent
human
counterpart
dc
besid
author
demonstr
block
dc
migrat
skin
hinder
cell
activ
respons
subcutan
bacteri
solubl
antigen
challeng
ablat
langerin
ddc
reduc
cell
immun
strength
corrobor
notion
migratori
dc
complement
lnresid
dc
effect
adapt
respons
nonetheless
role
lc
activ
cell
still
uncertain
probabl
due
controversi
function
properti
innat
subset
despit
synerg
effect
ln
resid
migratori
dc
seem
undoubt
inde
allenspach
colleagu
report
ag
present
lnresid
dc
hour
infect
requir
entrap
agspecif
cell
drain
ln
favor
optim
activ
cell
migratori
dc
arriv
ln
mani
hour
later
emerg
therefor
anoth
aspect
consid
identif
efficaci
adjuv
concern
type
dc
subset
target
consequenti
effect
adjuv
imprint
subset
adjuv
play
pivot
role
determin
tissueresid
dc
mobil
drain
ln
effici
cell
polar
inde
ddc
acquir
mobil
subcutan
inject
adjuv
cpg
lp
one
papain
follow
contact
sensit
dibutyl
phthalat
aceton
moreov
ddc
suffici
promot
respons
lc
support
evid
underscor
addit
polar
capabl
adjuv
also
target
dc
subset
must
consid
elicit
specif
adapt
immun
inde
antoni
colleagu
report
differenti
immun
respons
dc
target
ag
adjuv
either
cpg
odn
flagellin
addit
enhanc
efficaci
vaccin
coincid
deliveri
ag
prr
adjuv
apc
play
crucial
role
encourag
evid
highlight
import
conjug
ag
prr
adjuv
sinc
improv
ag
uptak
humor
cellular
respons
compar
vaccin
ag
codeliv
free
tlr
ligand
find
strengthen
notion
adjuv
formid
chief
shape
immun
respons
must
select
outcom
promot
chemic
associ
ag
interest
tradit
vaccin
approach
consist
administr
live
attenu
microorgan
sever
innov
strategi
emerg
address
need
effici
vaccin
especi
diseas
critic
treat
cancer
infecti
diseas
alreadi
mention
main
purpos
convey
ag
adjuv
targetingmolecul
uniqu
compound
increas
efficaci
agspecif
immun
respons
address
issu
differ
approach
explor
current
investig
shown
figur
recombin
antibodi
rab
repres
feasibl
option
approach
exploit
possibl
chemic
fuse
peptid
ag
adjuv
targetingmolecul
ab
tailor
dc
target
addit
rab
singlechain
fragment
variabl
scfv
reveal
appeal
strategi
due
reduc
size
enhanc
infiltr
tissu
solid
tumor
approach
involv
use
nanocarri
vehicl
promis
solut
target
phagocyt
inde
use
particul
materi
nanoparticl
np
best
candid
deliveri
system
sinc
manipul
effici
predominantli
target
phagocyt
possibl
thank
versatil
np
due
larg
amount
exist
differ
nanomateri
ii
possibl
adjust
size
morpholog
deform
great
precis
iii
possibl
load
virtual
differ
type
drug
molecul
viral
vectorsbas
vaccin
viruslik
particl
reli
intrins
capabl
virus
infect
cell
exploit
proteinencod
machineri
allow
express
cytosol
engin
plasmidgen
ag
costimulatori
molecul
cytokin
adjuv
provid
base
strong
ctl
induct
hand
nake
dna
directli
inject
conjug
nanocarri
favor
specif
target
easi
design
nanocarriersbas
vaccin
along
multicompon
load
featur
improv
target
specif
subset
shape
immun
respons
favor
applic
sever
field
cancer
set
nanocarri
allow
avoid
kill
healthi
cell
deliv
tumor
ag
dna
encod
peptid
apc
induc
specif
antitumor
respons
inde
np
allow
endocytosi
mhc
present
class
ii
elicit
broad
adapt
immun
even
cancer
cell
rosalia
colleagu
design
polymerbas
biodegrad
poli
lacticcoglycol
acid
plga
np
load
ag
poli
c
coat
agonist
ab
multifunct
strategi
result
effici
select
deliveri
np
dc
vivo
upon
sc
inject
induc
prime
cell
tumor
associ
ag
increas
tumorbear
mice
surviv
plga
np
carri
poorli
immunogen
melanomaderiv
antigen
tyrosinaserel
protein
along
lipid
manag
break
immunotoler
act
tumorantigen
inde
administr
abovement
np
result
antigenspecif
ctl
respons
character
product
increas
proinflammatori
cytokin
tumor
microenviron
tme
anoth
nanocarrierbas
approach
reli
liposom
selfassembl
vesicl
compos
lipid
bilay
high
function
properti
besid
maji
colleagu
report
uptak
dc
cation
liposom
local
endosom
compart
allow
ag
present
preferenti
mhc
exclud
mhc
ii
ag
present
suggest
crucial
role
antitumor
antivir
immun
support
th
respons
addit
use
np
target
dcspecif
receptor
becom
attract
strategi
vaccin
develop
due
enforc
effici
immun
respons
compar
genericdeliv
approach
report
character
dc
receptor
current
investig
scenario
tailoredvaccin
shown
tabl
ctype
lectin
receptor
mediat
endocytosi
phagocytosi
low
ph
endosom
promot
drift
toward
crosspresent
importantli
bind
antigen
induc
antigen
present
mhc
crosspresent
mhc
ii
highli
specif
express
cdc
monocyt
human
murin
pdc
ln
resid
migrat
dc
inde
dc
constitut
human
counterpart
murin
dc
share
receptor
releas
activ
cell
axi
necessari
robust
ctl
respons
dc
main
crosspres
dc
human
thu
appear
promis
ctlmediat
respons
tumor
viral
infect
specif
subset
character
express
may
exploit
fulli
activ
dc
sinc
antibodi
bind
lead
rapid
intern
tlrpathway
activ
prevent
proinflammatori
cytokin
product
full
matur
dc
convers
caminschi
li
independ
demonstr
potenti
target
result
enhanc
humor
immun
independ
pathway
even
absenc
adjuv
target
induc
enhanc
cell
prolifer
vivo
support
b
cell
immun
compar
target
anoth
endocyt
receptor
discuss
later
independ
use
adjuv
cpg
year
later
differ
author
demonstr
strong
humor
respons
endors
establish
follicular
helper
cell
memori
even
upon
vaccin
glycoprotein
hsv
mice
nonhuman
primat
promis
result
confirm
also
human
vitro
set
dc
final
efficaci
target
evalu
deliveri
poorli
immunogen
virusderiv
antigen
park
colleagu
manag
confer
specif
humor
respons
protect
upon
reinfect
thu
exploit
specif
express
receptor
special
dc
crosspresent
combin
ligand
enhanc
antivir
anticanc
respons
combin
robust
humor
immun
kda
endocyt
receptor
cysteinerich
domain
fibronectin
type
ii
domain
ctype
lectinlik
domain
well
intern
sequenc
cytoplasm
tail
thu
mediat
crosspresent
clathrin
dynamindepend
receptormedi
endocytosi
inde
express
profession
crosspres
dc
dc
subtyp
dc
display
low
level
receptor
addit
found
dermalinterstiti
dc
lc
thu
guarante
ag
deliveri
skinresid
lnresid
profession
apc
human
share
among
cdc
monocyt
b
cell
pdc
granulocyt
nk
cell
lymphocyt
express
low
level
receptor
addit
regul
molecul
recycl
late
endosom
promot
also
mhc
ii
present
cell
lc
steinman
nussenzweig
address
molecul
improv
vaccin
efficaci
sinc
take
advantag
rab
conjug
ova
peptid
demonstr
sc
inject
compound
lead
strong
immun
dc
activ
support
mab
otherwis
toler
ova
peptid
occur
inde
divers
prr
agonist
antibodi
crosslink
induc
dc
matur
furthermor
year
later
combin
strategi
report
confer
protect
melanoma
intranas
influenza
infect
viral
set
rab
chemic
coupl
hiv
gag
protein
test
vitro
blood
cell
deriv
hivinfect
donor
reveal
effici
expans
lymphocyt
differ
donor
indic
dc
lead
gener
differ
peptid
singl
protein
moreov
vaccin
base
filament
bacteriophag
fd
present
scfv
effici
induc
dc
matur
via
activ
pathway
without
adjuv
elicit
potent
antitumor
respons
compar
nontailor
ag
deliveri
intriguingli
orphan
specif
ligand
proven
necessari
cpg
uptak
eventu
dc
activ
molecul
belong
tnf
receptor
famili
express
sever
cell
type
among
dc
emerg
receptor
human
chaperon
heat
shock
protein
hsp
mediat
intern
peptid
bound
moreov
upon
activ
cell
transient
express
allow
crosslink
dc
complet
matur
notion
appear
interest
molecul
target
dcbase
vaccin
strategi
inde
engin
antibodi
chemic
structur
schjetn
colleagu
demonstr
efficaci
engag
confer
protect
myeloma
lymphomaderiv
ag
moreov
coadministr
two
dnabas
vaccin
encod
either
footandmouth
diseasederiv
ag
transient
increas
endogen
antibodi
allow
efficaci
dc
activ
effici
develop
agspecif
cell
immun
compar
administr
dna
encod
ag
alon
promis
result
obtain
vaccin
overexpress
mantl
cell
lymphoma
mcl
thank
algorithm
analysi
chen
colleagu
identifi
three
peptid
effici
bind
mhc
class
dc
potenti
overexpress
mcl
patient
gener
rab
target
effici
deliv
tumor
associ
ag
dc
mount
cell
respons
patientsderiv
peripher
blood
mononuclear
cell
thu
repres
specif
dctarget
molecul
use
combin
target
approach
support
specif
dc
activ
avoid
toler
induc
robust
cell
immun
evalu
vaccin
strategi
cancer
patient
compulsori
take
account
one
hallmark
cancer
avoid
immun
destruct
promot
toler
disarm
immun
system
orchestr
antitumor
respons
involv
multipl
protagonist
mediat
among
cytotox
cell
nk
cell
whose
activ
support
dc
furthermor
dcsbase
vaccin
emerg
effici
promot
cell
immun
compar
peptidebas
vaccin
approach
thu
much
effort
made
improv
strategi
dcsbase
vaccin
neoplast
diseas
amelior
prognosi
erad
primari
tumor
metastas
two
differ
approach
address
ex
vivo
gener
autolog
puls
dc
direct
vivo
target
dc
previous
discuss
former
strategi
provid
better
control
matur
activ
state
dc
specif
load
ag
select
dc
subset
despit
intens
work
need
gener
vaccin
sinc
person
patient
subset
dc
feasibl
gener
vitro
collect
ex
vivo
limit
access
ag
function
driven
subset
divers
vivo
target
method
allow
gener
larg
amount
vaccin
onestep
procedur
target
divers
dc
subset
natur
environ
dcsbase
vaccin
gener
efficaci
antitumor
respons
evalu
mainli
relat
capabl
establish
specif
antitumorassoci
ag
taa
immun
ii
overcom
tolerogen
statu
promot
tme
select
highli
immunogen
ag
multipl
solut
test
whole
tumor
lysat
kill
tumor
cell
synthet
long
peptid
slp
full
length
protein
transfect
electropor
dna
mrna
code
taa
transduct
lentivir
vector
neoantigen
avail
elev
number
antigen
incub
dc
whole
tumor
lysat
autolog
tumor
cell
allow
present
multipl
epitop
load
mhc
class
ii
lead
th
cytotox
respons
inde
sever
clinic
trial
current
evalu
benefit
obtain
use
approach
slp
aa
long
peptid
crosspres
dc
current
investig
preclin
clinic
set
compar
short
synthet
peptid
use
slp
lack
necess
know
patient
hla
haplotyp
thu
permit
full
exploit
larger
cohort
peopl
moreov
slp
administr
dc
lead
enhanc
cell
activ
sinc
engulf
rapidli
escap
endolysosom
follow
path
mhc
class
present
fundament
antitumor
respons
inde
slp
dcsbase
vaccin
show
promis
result
term
safeti
immunogen
preclin
clinic
set
gain
attent
context
human
papilloma
viru
cervic
ovarian
colorect
cancer
display
immunogen
capac
term
antibodi
product
cell
activ
deliv
adjuv
poli
iclc
compar
slp
full
length
protein
emerg
dc
process
slp
better
full
length
protein
due
slower
process
rout
latter
display
concern
transfect
electropor
dc
mrna
dna
encod
taa
also
costimulatori
molecul
cytokin
enforc
adapt
immun
proven
efficaci
induc
antitumor
cell
expans
mediat
dc
target
similar
approach
regard
vivo
lentivir
transduct
dc
display
versatil
gene
deliveri
effici
transduct
nondivid
cell
dc
inde
bryson
et
al
conceiv
multifunct
vaccin
compos
modifi
lentiviru
whose
glycoprotein
directli
target
dcsign
dc
load
breast
cancer
ag
alpha
lactalbumin
receptor
tyrosin
kinas
singl
inject
compound
provid
tumor
selfagsspecif
cell
immun
reduc
tumor
growth
despit
improv
deriv
advanc
strategi
last
year
neoantigen
becom
appeal
tumor
progress
cancer
cell
give
rise
neoantigen
novel
ag
differ
selftumor
ag
deriv
tumorspecif
mutat
therefor
predict
tool
rna
mutanom
deepsequenc
allow
identif
specif
nonselfag
fundament
strong
cell
immun
inde
sever
clinic
trial
current
investig
potenti
neoantigen
emerg
differ
strategi
ag
select
explor
even
though
one
strategi
may
result
enforc
antitumor
immun
compar
anoth
still
issu
tme
neg
influenc
immun
system
face
inde
tme
activ
suppress
activ
immun
system
tumor
cell
secret
immunosuppress
cytokin
vascular
endotheli
growth
factor
macrophag
colonystimul
factor
transform
growth
factor
even
though
cytokin
display
controversi
role
depend
patholog
context
gener
promot
dc
tolerogen
limit
activ
increas
express
protumor
molecul
program
cell
death
indoleamin
ido
therefor
tolerogen
dc
lead
cell
anergi
treg
expans
respons
inhibit
phenotyp
character
immun
cell
isol
breast
cancer
patient
highlight
function
alter
dc
nk
cell
promot
antitumor
respons
furthermor
tumor
cell
retain
dc
tme
prevent
migrat
drain
ln
promot
metastat
address
issu
ex
vivo
gener
dcsbase
vaccin
directli
administ
intranod
dc
puls
tumor
peptid
administ
patient
stage
iv
melanoma
gener
tumorspecif
cell
respons
improv
surviv
reduc
tolerogen
influenc
tme
dc
posit
role
gmcsf
improv
dc
surviv
respons
current
exploit
clinic
trial
like
phase
iii
trial
dctumor
cell
fusion
vaccin
administ
associ
gmcsf
treat
renal
cancer
similarli
other
focus
attent
fmslike
tyrosin
kinas
anoth
crucial
dc
growth
factor
combin
compound
inde
shown
increas
efficaci
protein
rnabas
vaccin
due
matur
effect
dc
addit
effort
made
counteract
tolerogen
influenc
tme
includ
use
ido
inhibitor
coadministr
molecul
increas
efficaci
dcsbase
vaccin
term
enforc
intratumor
cell
respons
traffick
memori
cell
observ
preclin
model
glioblastoma
parallel
sever
clinic
trial
aim
evalu
efficaci
dcsbase
vaccin
combin
agent
tolerogen
marker
address
cancer
immunotherapi
dcsbase
vaccin
ido
inde
silenc
approach
reduc
express
ido
dc
vaccin
preclin
model
result
decreas
cell
apoptosi
reduc
number
treg
decreas
tumor
size
compar
mice
receiv
agsload
dc
without
ido
silenc
ido
inhibitor
dc
vaccin
current
test
phase
ii
clinic
trial
approach
explor
differ
scenario
evalu
effici
therapeut
combin
seem
move
toward
person
vaccin
cancer
patient
review
underscor
crucial
role
dc
orchestr
immun
respons
therefor
great
interest
target
cell
novel
vaccin
strategi
report
exampl
differ
approach
aim
amplifi
effici
immun
cancer
infecti
diseas
inde
urgent
need
vaccin
relev
newli
emerg
diseas
ineffect
current
therapi
deepen
mechan
underli
patholog
may
provid
cue
appropri
design
vaccin
merg
divers
tailor
strategi
could
enforc
immun
system
matter
fact
suggest
act
differ
front
design
new
vaccin
sinc
sever
factor
must
consid
target
dc
subset
special
initi
desir
cellular
humor
immunitymemori
ii
adjuv
strengthen
drive
b
cell
respons
iii
fine
optim
select
immunogen
ag
drive
enforc
respons
iv
novel
strategi
convey
ag
adjuv
dc
v
rout
administr
start
notion
last
decad
enorm
effort
made
tailor
vaccin
strategi
new
technolog
well
recent
advanc
allow
extrem
flexibl
design
vaccin
shape
follow
outcom
nowaday
research
smart
tool
manipul
immun
respons
prophylact
therapeut
vaccin
abovement
find
pave
way
possibl
therapeut
approach
theoret
applic
patholog
context
despit
encourag
evid
sever
limit
issu
still
overcom
inde
vaccin
pass
phase
clinic
trial
either
toxic
issu
lack
immunogen
individu
miss
part
answer
question
could
sit
human
genet
popul
variabl
syngen
anim
model
ideal
set
system
push
although
constitut
necessari
use
step
preced
clinic
trial
moreov
translat
vaccin
test
vivo
experi
anim
ex
vivo
human
cell
often
opt
choic
blood
human
cell
case
vaccin
administ
skin
complet
differ
dcsbase
milieu
crucial
idoyaga
colleagu
dissect
interindividu
variabl
skinresid
dc
stress
need
shed
light
effect
genet
environ
imprint
dc
compulsori
decod
complex
scenario
human
divers
provid
person
therapi
increas
efficaci
omic
era
system
biolog
comput
model
integr
huge
dataset
address
urgent
need
inform
global
behavior
inde
genomewid
associ
studi
provid
insight
human
genet
variant
associ
immunogen
vaccin
therefor
integr
wet
evid
dri
notion
may
fasten
design
process
provid
effici
vaccin
strategi
predict
efficaci
author
list
made
substanti
direct
intellectu
contribut
work
approv
public
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
